Abstract:ABSTRACT Gut microbiota has demonstrated an increasingly important role in the onset and development of colorectal cancer (CRC). Nonetheless, the association between gut microbiota and KRAS mutation in CRC remains enigmatic. We conducted 16S rRNA sequencing on stool samples from 94 CRC patients and employed the linear discriminant analysis effect size algorithm to identify distinct gut microbiota between KRAS mutant and KRAS wild-type CRC patients. Transcriptome sequencing data from nine CRC patients were transformed into a matrix of immune infiltrating cells, which was then utilized to explore KRAS mutation-associated biological functions, including Gene Ontology items and Kyoto Encyclopedia of Genes and Genomes pathways. Subsequently, we analyzed the correlations among these KRAS mutation-associated gut microbiota, host immunity, and KRAS mutation-associated biological functions. At last, we developed a predictive random forest (RF) machine learning model to predict the KRAS mutation status in CRC patients, based on the gut microbiota associated with KRAS mutation. We identified a total of 26 differential gut microbiota between both groups. Intriguingly, a significant positive correlation was observed between Bifidobacterium spp. and mast cells, as well as between Bifidobacterium longum and chemokine receptor CX3CR1. Additionally, we also observed a notable negative correlation between Bifidobacterium and GOMF:proteasome binding. The RF model constructed using the KRAS mutation-associated gut microbiota demonstrated qualified efficacy in predicting the KRAS phenotype in CRC. Our study ascertained the presence of 26 KRAS mutation-associated gut microbiota in CRC and speculated that Bifidobacterium may exert an essential role in preventing CRC progression, which appeared to correlate with the upregulation of mast cells and CX3CR1 expression, as well as the downregulation of GOMF:proteasome binding. Furthermore, the RF model constructed on the basis of KRAS mutation-associated gut microbiota exhibited substantial potential in predicting KRAS mutation status in CRC patients. IMPORTANCE Gut microbiota has emerged as an essential player in the onset and development of colorectal cancer (CRC). However, the relationship between gut microbiota and KRAS mutation in CRC remains elusive. Our study not only identified a total of 26 gut microbiota associated with KRAS mutation in CRC but also unveiled their significant correlations with tumor-infiltrating immune cells, immune-related genes, and biological pathways (Gene Ontology items and Kyoto Encyclopedia of Genes and Genomes pathways). We speculated that Bifidobacterium may play a crucial role in impeding CRC progression, potentially linked to the upregulation of mast cells and CX3CR1 expression, as well as the downregulation of GOMF:Proteasome binding. Furthermore, based on the KRAS mutation-associated gut microbiota, the RF model exhibited promising potential in the prediction of KRAS mutation status for CRC patients. Overall, the findings of our study offered fresh insights into microbiological research and clinical prediction of KRAS mutation status for CRC patients.

Identifying Robust Microbiota Signatures and Interpretable Rules to Distinguish Cancer Subtypes

Identifying the Signatures and Rules of Circulating Extracellular MicroRNA for Distinguishing Cancer Subtypes

Detecting microbiome species unique or enriched in 20+ cancer types and building cancer microbiome heterogeneity networks

Comprehensive analysis of microbiota signature across 32 cancer types

Exploring the patient-microbiome interaction patterns for pan-cancer

Global Analysis of Microbiota Signatures in Four Major Types of Gastrointestinal Cancer

Machine learning-based approaches for cancer prediction using microbiome data

Multi-omics Analysis Revealed the Regulation Mode of Intratumor Microorganisms and Microbial Signatures in Gastrointestinal Cancer.

Identification of a brand intratumor microbiome signature for predicting prognosis of hepatocellular carcinoma

Pan-cancer analysis of microbiome quantitative trait loci

Multiomics-based molecular subtyping based on the commensal microbiome predicts molecular characteristics and the therapeutic response in breast cancer

A review of machine learning methods for cancer characterization from microbiome data

Robustness of cancer microbiome signals over a broad range of methodological variation

Identification of KRAS mutation-associated gut microbiota in colorectal cancer and construction of predictive machine learning model

Artificial Intelligence-Enabled Microbiome-Based Diagnosis Models for a Broad Spectrum of Cancer Types.

Utilizing tumor microenvironment microbial profiles and host gene expressions for survival subtyping in diverse types of cancers

Understanding the Role of the Microbiome in Cancer Diagnostics and Therapeutics by Creating and Utilizing ML Models

Identification of microbial markers associated with lung cancer based on multi‐cohort 16 s rRNA analyses: A systematic review and meta‐analysis

Study of Microbiomes in Aseptically Collected Samples of Human Breast Tissue Using Needle Biopsy and the Potential Role of in situ Tissue Microbiomes for Promoting Malignancy

Recognizing Pattern and Rule of Mutation Signatures Corresponding to Cancer Types

Predicting cancer immunotherapy response from gut microbiomes using machine learning models